TELA Bio, Inc. (TELA)
NASDAQ: TELA · Real-Time Price · USD
1.220
-0.015 (-1.21%)
Mar 31, 2025, 10:45 AM EDT - Market open
TELA Bio Revenue
In the year 2024, TELA Bio had annual revenue of $69.30M with 18.56% growth. TELA Bio had revenue of $17.65M in the quarter ending December 31, 2024, with 3.83% growth.
Revenue (ttm)
$69.30M
Revenue Growth
+18.56%
P/S Ratio
0.51
Revenue / Employee
$305,286
Employees
227
Market Cap
48.25M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TELA News
- 10 days ago - TELA Bio, Inc. (TELA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference - GlobeNewsWire
- 5 months ago - TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 5 months ago - TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire